Department of Gastroenterology, The First Medical Center of Chinese PLA General Hospital, Beijing.
The Second Hospital of Hebei Medical University, Shijiazhuang.
Int J Surg. 2024 Apr 1;110(4):2055-2064. doi: 10.1097/JS9.0000000000001120.
Current treatments for refractory benign esophageal strictures (BESs) often take several years and have poor effects. The authors propose a novel method of self-help inflatable balloon (SHIB) and evaluate its efficacy and safety.
A prospective, multicenter study was conducted from January 2019 to March 2022. All enrolled patients were diagnosed with refractory BESs and received SHIB. The primary endpoint was the clinical success rate at 12 months after removing SHIB. The secondary endpoints were the number of days of placing SHIB, and changes from baseline in BMI and health-related quality of life at 1, 3, 6, and 12 months.
The clinical success rate was 51.2% (21/41) with the median days of placing SHIB being 104.0 days (range: 62.0-134.5 days), which was higher in the endoscopic group compared to the caustic and surgery groups (63.3 vs. 28.6% vs. 0, P=0.025). All patients (100%) showed significant improvement in dysphagia scores during placing SHIB. Although 20 patients (48.8%) experienced recurrent stricture, the median stricture length was decreased (P<0.001) and the median intervention-free interval was prolonged (P<0.001). In all patients, the mean BMI at and health-related quality of life at 1, 3, 6, and 12 months were significantly increased compared with baseline (P<0.05). On multivariate analysis, stricture etiology and wearing time were independent predictors of recurrent stricture.
The SHIB has high efficacy and safety in treating refractory BESs of different origins, especially for endoscopic resection. Stricture etiology and wearing time were independent predictors of recurrent stricture.
目前治疗难治性良性食管狭窄(BES)的方法往往需要数年时间,且效果不佳。作者提出了一种新型的自膨式气囊(SHIB)治疗方法,并评估其疗效和安全性。
这是一项前瞻性、多中心研究,于 2019 年 1 月至 2022 年 3 月进行。所有入组患者均诊断为难治性 BES,并接受 SHIB 治疗。主要终点为 SHIB 取出后 12 个月的临床成功率。次要终点为 SHIB 放置天数,以及 1、3、6 和 12 个月时 BMI 和健康相关生活质量的变化。
临床成功率为 51.2%(21/41),SHIB 放置中位数为 104.0 天(范围:62.0-134.5 天),内镜组高于腐蚀性和手术组(63.3% vs. 28.6% vs. 0,P=0.025)。所有患者(100%)在放置 SHIB 期间吞咽困难评分均显著改善。尽管 20 名患者(48.8%)出现再狭窄,但狭窄长度中位数降低(P<0.001),无干预间隔时间延长(P<0.001)。所有患者在 1、3、6 和 12 个月时的平均 BMI 和健康相关生活质量均显著高于基线(P<0.05)。多变量分析显示,狭窄病因和佩戴时间是再狭窄的独立预测因素。
SHIB 治疗不同病因难治性 BES 的疗效和安全性较高,尤其适用于内镜下切除。狭窄病因和佩戴时间是再狭窄的独立预测因素。